{"id":75467,"date":"2026-07-03T00:48:19","date_gmt":"2026-07-03T00:48:19","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/75467\/"},"modified":"2026-07-03T00:48:19","modified_gmt":"2026-07-03T00:48:19","slug":"abbisko-astrazeneca-to-test-lumipodlin-with-tagrisso","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/75467\/","title":{"rendered":"Abbisko, AstraZeneca to test lumipodlin with Tagrisso"},"content":{"rendered":"

SHANGHAI, July 1, 2026 \/PRNewswire\/ — Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE\/STO\/NYSE: AZN<\/a>) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC). As a multicenter, open-label Phase I\/II clinical study, the combination will evaluate the safety and efficacy of Abbisko’s first-in-class oral small-molecule PD-L1 inhibitor, lumipodlin (ABSK043), in combination with AstraZeneca’s third-generation EGFR-TKI, TAGRISSO\u00ae (osimertinib), for the treatment of patients with EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC. On May 20, 2026, the investigational new drug (IND) application for the combination study was cleared by the National Medical Products Administration (NMPA). This Phase II study will be led by Abbisko, and both Abbisko and AstraZeneca will share responsibilities for the clinical trial.<\/p>\n

\n
\n \"Logo
\n <\/a>\n <\/p>\n

Lumipodlin is a potentially first-in-class oral small molecule PD-L1 inhibitor with unique properties beyond its route of administration. Currently, third-generation EGFR-TKIs represented by osimertinib have become the front-line standard of care for EGFR-mutated NSCLC. However, patients with EGFR-mutant and high PD-L1 expression derive less benefit from EGFR-TKIs than those with low or negative PD-L1 expression[1],[2]. There is a long-standing unmet medical need for patients with EGFR mutated, PD-L1 positive NSCLC.<\/p>\n

References
[1]\u00a0 Brown H, Vansteenkiste J, Nakagawa K, et al. Programmed cell death ligand 1 expression in untreated EGFR mutated advanced NSCLC and response to osimertinib versus comparator in FLAURA. J Thorac Oncol. 2020;15(1):138\u2013143.<\/p>\n

[2]\u00a0 Niu J, Jing X, Xu Q, et al. Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs. Future Oncol. 2024;20(32):2481-2490.<\/p>\n

About Lumipodlin (ABSK043)
Lumipodlin is a novel, orally bioavailable, highly selective small molecule PD-L1 inhibitor independently developed and wholly owned by Abbisko Therapeutics. Tumor cells can exploit immune checkpoints such as PD-1 and its ligand PD-L1 to evade immune detection and clearance, thereby suppressing or limiting T-cell responses. Lumipodlin selectively binds to the PD-L1 receptor and induces its internalization from the cell surface, effectively inhibiting the PD-1\/PD-L1 interaction and alleviating PD-L1-mediated suppression of T-cell activation. In preclinical models, lumipodlin has demonstrated anti-tumor efficacy comparable to approved PD-L1 antibodies. While several PD-1\/PD-L1 monoclonal antibodies have been approved worldwide, there are currently no approved orally bioavailable PD-1\/PD-L1 small molecule drugs. Lumipodlin is currently being explored in an ongoing Phase I clinical trial for advanced solid tumors in Australia and China.<\/p>\n

About Tagrisso
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in\u00a0EGFRm NSCLC, including against central nervous system metastases. Tagrisso (40mg and 80mg QD oral tablets) has been used to treat more than one million patients across its indications worldwide and AstraZeneca continues to explore Tagrisso as a treatment for patients across multiple stages of EGFRm NSCLC.<\/p>\n

About Abbisko Therapeutics
Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused\u00a0biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was\u00a0established by a group of seasoned drug hunters with rich research & development and managerial expertise from top\u00a0multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and\u00a0immuno-oncology.<\/p>\n

Please visit www.abbisko.com<\/a>\u00a0for more information.<\/p>\n

About AstraZeneca
AstraZeneca (LSE\/STO\/NYSE: AZN<\/a>) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com\u00a0and follow the Company on social media @AstraZeneca.<\/p>\n

Disclaimer: The indication for the combination therapy referenced in this document has not been approved in China. AstraZeneca and Abbisko Therapeutics do not recommend the use of any unapproved medicines.<\/p>\n

\"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/abbisko-therapeutics-and-astrazeneca-enter-a-strategic-collaboration-to-conduct-the-clinical-trial-of-lumipodlin-absk043-a-first-in-class-oral-pd-l1-inhibitor-in-combination-with-tagrisso-for-nsclc-302816115.html<\/a><\/p>\n

SOURCE Abbisko<\/p>\n

<\/p>\n


\n FAQ \n <\/p>\n


\n
\n <\/p>\n

What did AstraZeneca (AZN) announce about its collaboration with Abbisko Therapeutics for NSCLC?<\/p>\n


\n AstraZeneca and Abbisko announced a strategic collaboration to develop an IO-TKI combination therapy for EGFR-mutated, PD-L1 positive NSCLC. According to Abbisko, the partnership centers on lumipodlin (ABSK043) combined with AstraZeneca\u2019s third-generation EGFR-TKI, TAGRISSO (osimertinib), in a Phase I\/II clinical trial. \n <\/p>\n


\n <\/p>\n

What is lumipodlin (ABSK043) in AstraZeneca\u2019s NSCLC collaboration with Abbisko?<\/p>\n


\n Lumipodlin (ABSK043) is described as a potentially first-in-class oral small-molecule PD-L1 inhibitor. According to Abbisko, it will be evaluated in combination with AstraZeneca\u2019s TAGRISSO in a Phase I\/II study for EGFR-mutated, PD-L1 positive locally advanced or metastatic non-small cell lung cancer. \n <\/p>\n


\n <\/p>\n

What are the key details of the Phase I\/II lumipodlin and TAGRISSO trial for AZN investors?<\/p>\n


\n The study is a multicenter, open-label Phase I\/II clinical trial in EGFR-mutated, PD-L1 positive locally advanced or metastatic NSCLC. According to Abbisko, the trial will assess safety and efficacy of lumipodlin plus TAGRISSO, with Abbisko leading Phase II and both companies sharing responsibilities. \n <\/p>\n


\n <\/p>\n

When was the IND cleared for the lumipodlin and TAGRISSO NSCLC combination study?<\/p>\n


\n The investigational new drug application for the lumipodlin and TAGRISSO combination was cleared on May 20, 2026. According to Abbisko, China\u2019s National Medical Products Administration (NMPA) granted this clearance, enabling the planned Phase I\/II multicenter, open-label clinical study in EGFR-mutated, PD-L1 positive NSCLC. \n <\/p>\n


\n <\/p>\n

Which NSCLC patients will the AstraZeneca and Abbisko lumipodlin trial target?<\/p>\n


\n The trial will target patients with EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC. According to Abbisko, current third-generation EGFR-TKIs like TAGRISSO provide less benefit in this subgroup, indicating a long-standing unmet medical need for these patients in clinical practice. \n <\/p>\n


\n <\/p>\n

How does TAGRISSO feature in AstraZeneca\u2019s new NSCLC trial with Abbisko?<\/p>\n


\n TAGRISSO (osimertinib), AstraZeneca\u2019s third-generation EGFR-TKI, will be combined with lumipodlin in the new trial. According to Abbisko, TAGRISSO is already a front-line standard of care for EGFR-mutated NSCLC and will be evaluated in EGFR-mutated, PD-L1 positive patients within this Phase I\/II study. \n <\/p>\n


\n <\/p>\n","protected":false},"excerpt":{"rendered":"SHANGHAI, July 1, 2026 \/PRNewswire\/ — Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter, HKEX code: 02256.HK) today announced…\n","protected":false},"author":2,"featured_media":75468,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[34039,34154,11153,21721,7747,34153,29793,34155],"class_list":["post-75467","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-abbisko-therapeutics","tag-absk043","tag-astrazeneca","tag-azn","tag-clinical-trial","tag-lumipodlin","tag-nsclc","tag-tagrisso"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116853296707702426","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/75467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=75467"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/75467\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/75468"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=75467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=75467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=75467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}